Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Collaborative Appoints New President

NEW YORK, Jan 5 – Genomics Collaborative, a SNP-detection company, said Friday it has appointed Michael Dougherty as president and chief operating officer.

Dougherty was previously president and CEO of biotech company Magainin Pharmaceuticals, where he will remain non-executive chairman of the board.

“We view Michael’s arrival as another step toward CGI positioning itself to develop genomic based products,” CEO Michael Pellini said in a statement.

  Based in Cambridge, Mass., Genomics Collaborative is a privately held company that recently raised $36 million from investors including Invesco Private Capital, Oracle Partners, AFTC Funds, and the Economic Development Board of Singapore.

The company has partnership agreements with companies such as Lynx Therapeutics, Gene Logic, Qiagen, and Genometrix.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.